New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 3, 2012
05:55 EDTSQNMSequenom concerns should alleviate with publication, says Piper Jaffray
Piper Jaffray believes the Genetics in Medicine article showing Sequenom's MaterniT21's ability to accurately detect trisomy 13 and 18 should alleviate concerns of the test's ability to detect rarer chromosomal abnormalities. The firm keeps an Overweight rating on Sequenom shares with a $6.25 price target.
News For SQNM From The Last 14 Days
Check below for free stories on SQNM the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 30, 2014
08:39 EDTSQNMSequenom should be bought following solid Q2, says Maxim
Subscribe for More Information
July 29, 2014
18:35 EDTSQNMOn The Fly: After Hours Movers
Subscribe for More Information
16:33 EDTSQNMSequenom reports Q2 adjusted EPS (7c), consensus (11c)
Subscribe for More Information
16:32 EDTSQNMSequenom enters license agreement with Mayo Medical Laboratories
Subscribe for More Information
July 21, 2014
11:21 EDTSQNMSequenom VisibiliT launch unlikely to have near-term impact, says Ladenburg
Subscribe for More Information
07:02 EDTSQNMSequenom subsidiary launched VisibiliT test in international markets
Sequenom announced that its wholly owned subsidiary, Sequenom Laboratories, will soon launch the VisibiliT laboratory-developed test in international markets. The VisibiliT test utilizes maternal age, fetal fraction and the relative amount of chromosomal material for chromosomes 21 and 18 to generate a highly accurate, personalized risk score.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use